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A b s t r a c t  
Cancer one of the deadliest disease and resistance of cancer cells has been the major issue in both 
the modern molecular targeted therapeutics as well as in the conventional chemotherapeutics. As 
on date chitosan has been the ideal choice as a carrier for delivering anticancer drugs like 
doxorubicin and cisplatin for targeted delivery. The present study focusses on the fabrication of 
chitosan nanoparticles using TPP by ionic gelation method loaded with 5-FU, an anticancer drug. 
The morphology of the nanoparticles synthesized were analysed using SEM and the size, zeta 
potential using particle size analyser. The mechanism of drug release was studied by fitting the 
release kinetics with Peppas model. Cellular uptake of the drug was analysed and using MTT the 
cytotoxicity & metabolic activity of the normal and the cancerous cells were evaluated. Results of the 
study showed that the synthesized nanoparticles possessed a positive charge and the release of the 
drug was through diffusion and degradation mediated. Also the cellular uptake of the drug showed 
the amount of drug uptake reduced with the cancerous cell as the time increase which was further 
confirmed using the MTT assay which showed the metabolic activity of the cancerous cell got 
reduced. The results of the study showed that the fabricated nanoparticles could potentially be used 
as a carrier towards the treatment of cancer. 
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Introduction 
Cancer is an extremely heterogeneous complex disease 
characterized by indeterminate growth of cells with a cluster of 
disorders. The malady of cancer has troubled humans inspite of 
witnessing an imposing progress in the field of cancer biology [1].  
There are several types of cancers that are still incurable or 
possess a severe adverse effect post treatment inspite of having 
attractive advances. Significant amount of efforts are being made 
to resolve the problem and enormous amount of research are 
being carried out towards the anticancer therapy and natural tissue 
healing, in particular towards targeted delivery of drugs [2].  Some 
of the drawbacks of the conventional chemotherapies include that 
of the nonspecific distribution of the drug in both the cancerous and 
normal cells. These nonspecific distributions not only affect the 
normal cells but limit the dosage of the drug on the target site 
resulting in a suboptimal treatment. Yet another method is the 
molecular targeted therapy which has attracted many scientist and 
researchers but it is limited by the lack in specificity compared to 
the conventional chemotherapeutic agents. However, the 
development of resistance in cancer cells has been the major issue 
in both the modern molecular targeted therapeutics as well as in 
the conventional chemotherapeutics [3-5]. 
The idea of creating tiny particles alias magic bullets by Ehrlich 
enabling the delivery of active molecules at a specific site of the 
body has s been the prime interest in the field of pharmaceutical 
sciences [6]. The fusion of nanotechnology and medicine so called 
nanomedicine is one of the most encouraging approaches in 
addressing diseases concomitant with conventional drug delivery 
methods. Many approach systems based on the polymeric 
nanoparticles (NPs) have been the keystone towards the progress 
in nanomedicine [7-8]. One of the important challenges over the 
last few decades has been the use of nanoparticles as a potential 
carrier of drug as their design enhances the pharmacological and 
therapeutic effects in addition to a reduction in toxic side effects. 
Nanoparticles decrease the drug doses and improve the patient 
compliance by allowing the continuous & controlled release of the 
therapeutic drugs within the desired level and also help in the 
targeted delivery of the drug to their intended tissues & cells [9-12].  
Also it was observed that the therapeutic agents were much stable 
in the GIT when encapsulated inside a nanoparticle system. The 
carrier aids in improving the cellular uptake of the drug, deliver an 
elicited release at ease, even reveal in targeting when attached 
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with a targeting moiety and could control the physiochemical 
properties of the therapeutic agent. The nanoparticulate drug 
carriers are developed using either synthetic or natural polymer or 
by a combination of both. Amongst the various natural polymers 
that are available chitosan is one of the most widely used 
biopolymer for the preparation of nanoparticles and extensive 
amount of research has been reported so far. Chitosan is 
synthesized by the alkaline deacetylation of chitin, as itÊs made up 
of N-acetylglucosamine and glucosamine with varying viscosity, 
molecular weight and degree of deacetylation [13-16].  
Chitosan is the polymer of choice for many researchers as they 
possess excellent biocompatibility, biodegradability, low cost, are 
mucus adhesive and so on which made them an ideal choice as a 
carrier for delivering anticancer drugs like doxorubicin and cisplatin 
for targeted delivery. Also the application of chitosan nanoparticles 
in the plasmid DNA delivery, siRNA, topical immunization and the 
characteristics like anti-microbial, wound healing, hypo-
cholesterolemic & anti-ulcer activity comes as handy and makes it 
an ideal carrier for drug delivery [17, 18]. 
The present study focuses on the synthesis of chitosan 
nanoparticles using TPP solution by the ionic gelation method. The 
nanoparticles prepared were loaded with 5-FU anticancer drug and 
their in vitro release kinetics was analysed followed by fitting with 
Peppas model to study the mechanism behind the release kinetics.  
The cellular uptake of the drug and the biocompatibility of the 
prepared samples were evaluated. 
Materials and methods 
Chitosan and sodium tripolyphosphate (TPP) were purchased from 
Sigma Aldrich. Acetic acid was obtained from TCI chemicals and 5-
FU was obtained from HI media. Molecular weight of chitosan was 
~1.2*105 Da with >90% degree of acetylation. 
 
Nanoparticles Preparation 
Chitosan nanoparticles were prepared by the process of ionic 
gelation method. Initially chitosan (0.1% (w/v)) was dissolved in 
0.05% aqueous acetic acid while the polyanionic solution was 
prepared by dissolving TPP (0.1% (w/v)) in deionised water. The 
polyanionic solution was added drop wise to the Chitosan solution 
under constant stirring and the nanoparticles were obtained 
spontaneously. The nanoparticles were centrifuged at 16,000 rpm 
for 30min, lyophilised and washed with distilled water. 
Nanoparticles were prepared with different concentrations (w/w) of 
TPP as given in table 1. The anticancer drug 5-FU (5 and 10wt%) 
was loaded onto the nanoparticles by adding it to the TPP solution 
at two different concentrations of 5 and 10wt%.  
 
Table 1 shows the various concentrations of chitosan and TPP 
(w/w). 
Model Chitosan (mg) TPP(mg) 
1 10 1 
2 10 2 
3 10 3 
Morphological Characterization 
SEM (HITACHI S-3400model) analysis was carried out to study the 
morphological character of the prepared models. The average size 
of the particle and zeta potential for the stability of the 
nanoparticles were determined using dynamic light scattering 
method (Malvern ZEN3600). 
 
In vitro Degradation  
The in vitro degradation studies were adopted from Hou et al [19].  
Briefly, the nanoparticles were incubated in 5mL of PBS containing 
lysozyme (0.1 mg/mL) at 37 oC with slow stirring. The degradation 
ratios were measured at varying times and the media was replaced 
once every week. The degradation ratios were expressed based on 
the difference in the initial weight of the nanoparticles to their 
weight after removal from the incubating media. The nanoparticles 
in PBS without lysozyme incorporation acted as control. 
 
Drug Release Kinetics 
The procedure adapted in release kinetics was as described in an 
earlier report [16]. Briefly, the drug loaded nanoparticles were 
immersed in 10mL PBS buffer at pH 6.2, followed by centrifugation. 
After centrifugation, the amount of drug released was determined 
spectrophotometrically at 266nm using UV spectrophotometer (PG 
Instruments) at a time interval of 5h for a period of 140 h. In order 
to study the mode of the release kinetics the obtained data were 
fitted in to the Peppas model [20-21]. 
 
Cellular Uptake of drug 
The in vitro cellular uptake of the drug from the nanoparticles was 
analysed using normal fibroblast (L929) and cancerous cells 
(HeLa, MG-63, MCF-7) by absorption measurements. The 5% and 
10% drug loaded nanoparticles were loaded onto 24 well plates 
with a cell concentration of 50,000 ă 60,000 cells/well followed by 
incubation. After incubation, the cells were washed carefully with 
PBS followed by trypsinization. A sonicator was used to lyse the 
collected cells and the amount of drug uptake was quantified using 
the UV Visible spectrophotometer at 266nm. All the experiments 
were carried out in triplicates. 
 
Biocompatibility Studies 
MTT assay was used to evaluate the biocompatibility of the 
prepared biomaterials and also for analysing the metabolic activity 
of the tumour cells. Briefly, the cell lines (both normal and tumor 
cells) were cultured using DulbeccoÊs modified EagleÊs medium 
supplemented with 1% penicillinăstreptomycin, 5% fetal bovine 
serum followed by seeding onto a T75 tissue culture flasks. In 
order to supply the cells with fresh nutrients, the media was 
changed every 48 hours thereby enhancing the cell growth. Once 
the cells were confluent they were subjected to trypsinization i.e., 
removal of the adherent cells. The metabolically active cell 
mitochondria of the living cell cause the reduction of yellow 
tetrazolium salt that is MTT resulting in the formation of violet 
formazan crystal. Finally the absorbance at 575nm was measured 
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spectrophotometrically using ELISA reader which was used to 
study the cytotoxic nature of the sample and the metabolic activity 
of the cells were analysed [16, 22].  
 
Statistical Analysis 
The data obtained from the studies were analysed using one-way 
ANOVA test and the statistical significance was set at 0.05. Origin 
8.0 version was used for the statistical analysis and the data were 
presented in the form of mean and variance. 
 
Results and Discussion 
Morphological Analysis 
Chitosan nanoparticles capable of degradation & prolonged 
circulation were prepared successfully using TPP. The formation of 
the nanoparticles was due to the character of the chitosan to form 
a rapid gel on contact with the polyanions. The NH3+ in chitosan 
gets electrostatically attracted to the negatively charged TPP 
thereby forming the ionically cross-linked nanoparticles. As 
reported in previous studies the solution colour changed from clear 
to opalescent with all the models on the addition of TPP to the 
chitosan solution and was attributed to the formation of 
nanoparticles. In addition, the drug 5-FU may have electrostatic 
attraction with the chitosan as it is negatively charged. 
 
 
Figure 1 SEM images of the nanoparticles synthesized a) at lower magnification b) at higher magnification 
 
 
Table 2 Average particle size and zeta potential values of the nanoparticles prepared 
 
 
 
 
 
 
 
The nanoparticles prepared exhibited a mean diameter between 
100nm to 272nm with the zeta potential values ranging between 40 
mV to 32mV (Table 2). The values of the zeta potential were 
observed to be higher when the concentration of the chitosan was 
increased. The results of the study obtained from SEM were in 
agreement with the one obtained by Aydin et al [9] and the 
particles size ranges were comparatively lower. It should be noted 
that the prepared nanoparticles possess the advantage of escaping 
the vasculature by means of the leaky endothelial cells and could 
possibly accumulate in the solid tumour cells by enhanced 
permeation and retention effect (EPR).  Being positively charged, 
these chitosan based nanoparticles might help in the passive 
targeting as the cationic group of chitosan may be attracted 
electrostatically to the negatively charged phospholipid head 
groups expressed on the tumour endothelial cells [23-25].   
 
In vitro Degradation 
 
 
 
Due to the hydrophilic nature of chitosan, it has the capability of 
absorbing enormous amount of aqueous solution, enduring 
degradation through hydrolysis, erosion and other biodegradation  
mechanisms which is consecutively governed by various other 
mechanisms. In the present study the in vitro degradation of 
chitosan in PBS and with PBS + lysozyme enzyme were evaluated. 
The results of the study were as anticipated in which the 
degradation of chitosan in PBS occurred at a slower rate in 
contrast to the rapid degradation observed with lysozyme. The 
ionic interaction of the polymer and its nature play a role in the 
degradation mechanisms.  This was further confirmed by the 
degradation mechanisms observed for the three models wherein, 
the models 2 & 3 with higher amount of TPP showed dawdling 
phase of degradation as compared to model 1 which showed a 
degradation of 85% in 50h. This was 5-10% higher than the other 
two models. The in vivo degradation rate of chitosan was much 
 Average Size in nm (5wt% 5-
FU) 
Zeta Potential in mV Average Size in nm 
(10wt% 5-FU) 
Zeta Potential in mV
Model 1 130 ă 280 40 μ 0.7 120 ă 210 39 μ 0.7
Model 2 100 ă 270 35 μ 0.4 100 ă 200 38 μ 0.5
Model 3 104 ă 275 33 μ 0.4 90 ă 195 36 μ 0.4
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Figure. 4:  Drug release profile of 5-FU from nanoparticles 
 
The release kinetics suggested that the drug release was in a 
sustained manner and could possibly help in targeting and 
destruction of the tumor cells.  In order to study the mechanism 
behind the release kinetics, the model was fitted on to the Peppas 
model (Figure 5). The slope of the release kinetics that was 
calculated from the log-log plot showed that the diffusion controlled 
power constant was close to 0.5. It was reported by Peppas et al 
that this kind of phenomenon is usually observed when the drug 
was released by the mechanism of diffusion and degradation [20, 
21]. The high water uptake chitosan plays a vital role in the release 
kinetics. The increase in the drug release was due to the presence 
of water channels provided by chitosan to the drug for diffusion as 
well as assisting in the degradation of the polymer itself since the 
mode of degradation for chitosan is via hydrolytic process. 
 
 
 
Figure. 5 Fitting of the release kinetics to Peppas model 
 
Cellular Uptake 
The cellular uptake of the drug by different cell lines, as shown in 
figure 6, showed that level of drug uptake in the cancerous cell 
lines were higher and over a period of time the amount of drug 
uptake declined which may be attributed to the death of the 
cancerous cells leading to the apparent lower amount of drug 
uptake. One of the important considerations for the nanoparticles 
for their biological application apart from the uptake profiles is their 
final subcellular location. 
This is important particularly in drug delivery as it is important for 
the nanoparticles to reach the target site in the cell interior apart 
from delivering the drug to the target tissue and this was observed 
by the decrease in the number of cancerous cells. In addition to the 
cellular uptake of the drug, the metabolic activity of the cancerous 
cell also plays a vital role. The decrease in the metabolic activity 
was confirmed using the MTT assay. 
 
 
Figure. 6 Cellular uptake of 5-FU by normal and cancerous cell 
lines 
 
Cytotoxicity Studies 
The cytotoxicity studies of the samples showed that the viability of 
the normal cells was unaffected by both the bare nanoparticles as 
well as the drug loaded CS NPs. On the other hand, the MTT 
assay showed that the metabolic activities of the cancerous cells 
were greatly influenced by the drug loaded nanoparticles. The 
normal cells viability percentage was higher than that of the 
cancerous cells. From figure 7, the viability of the normal cells 
could be found to be between 80-85% in all the cases of 
nanoparticles with and without drug. Similarly the viability of the 
MCF-7 cell lines showed a decline gradually with increase in the 
drug concentration. Reports showed that the decrease in the cell 
viability corresponds to either the slow or no proliferation in the 
cells, thereby affecting the metabolic activity of the cancer cell line 
MCF-7[31].  Also other type of cancer cells showed a decline in 
their viability with the exposure to the nanoparticles with drug and 
the cell viability of cancerous cell lines got reduced as there was an 
increase in the drug concentration which was obvious.  
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